1. Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
   Muhammad Tufail et al, 2024, Journal of Translational Medicine CrossRef
2. Role of ARPC2 in Human Gastric Cancer
   Jun Zhang et al, 2017, Mediators of Inflammation CrossRef
3. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation
   Qi Zhang et al, 2018, Biochemical and Biophysical Research Communications CrossRef
4. Fine Tuning Cell Migration by a Disintegrin and Metalloproteinases
   D. Dreymueller et al, 2017, Mediators of Inflammation CrossRef
5. MEK inhibitor, PD98059, promotes breast cancer cell migration by inducing β-catenin nuclear accumulation
   Ying Zhao et al, 2017, Oncology Reports CrossRef
6. Cyanidin‐3‐O‐glucoside and cisplatin inhibit proliferation and downregulate the PI3K/AKT/mTOR pathway in cervical cancer cells
   Xu Li et al, 2021, Journal of Food Science CrossRef
7. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
   Michael P. Menden et al, 2019, Nature Communications CrossRef
8. The role of tumor suppressor short non-coding RNAs on breast cancer
   Shokooh Salimimoghadam et al, 2021, Critical Reviews in Oncology/Hematology CrossRef
9. Secretome within the bone marrow microenvironment: A basis for mesenchymal stem cell treatment and role in cancer dormancy
   Hussam S. Eltoukhy et al, 2018, Biochimie CrossRef
10. Effects of ADAM2 silencing on isoflurane-induced cognitive dysfunction via the P13K/Akt signaling pathway in immature rats
    Bao-Juan Zhang et al, 2019, Biomedicine & Pharmacotherapy CrossRef
11. The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
    Simon Manuel Tria et al, 2023, Cancers CrossRef
12. Mass spectrometry-based proteomics revealed Glypican-1 as a novel ADAM17 substrate
    Rebeca Kawahara et al, 2017, Journal of Proteomics CrossRef
13. Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events
    Tobias Meißner et al, 2017, Molecular Case Studies CrossRef
14. Reciprocal control of ADAM17/EGFR/Akt signaling and miR-145 drives GBM invasiveness
    Yuduo Guo et al, 2020, Journal of Neuro-Oncology CrossRef
15. Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity
    Wei-wei Chen et al, 2021, Protein Expression and Purification CrossRef
16. Structural exploration of arylsulfonamide-based ADAM17 inhibitors through validated comparative multi-QSAR modelling studies
    Sandip Kumar Baidya et al, 2019, Journal of Molecular Structure CrossRef
17. Daphnoretin: An invasion inhibitor and apoptosis accelerator for colon cancer cells by regulating the Akt signal pathway
    Suyang Yu et al, 2019, Biomedicine & Pharmacotherapy CrossRef
18. siRNA and targeted delivery systems in breast cancer therapy
    Sepideh Mirzaei et al, 2022, Clinical and Translational Oncology CrossRef